ライフサイエンスコーパス: uveitis

1 is); included were 52 patients (84 eyes with uveitis).

2 isual loss and complications in intermediate uveitis.

3 cal implications in the laboratory workup of uveitis.

4 P (91%) had this already at the start of the uveitis.

5 immunopathology of VZV-associated posterior uveitis.

6 between vitamin D levels and the presence of uveitis.

7 Risk of incident uveitis.

8 f age or older who had active JIA-associated uveitis.

9 pared between EVD survivors with and without uveitis.

10 vitamin D levels and noninfectious anterior uveitis.

11 and uveitis or (2) ICD-9 code for syphilitic uveitis.

12 c biomarkers of sarcoidosis in patients with uveitis.

13 eye draining lymph nodes, but did not induce uveitis.

14 ne dysregulation in both thyroid disease and uveitis.

15 ing a potential novel therapy of MSC-Exo for uveitis.

16 life (VRQoL) in patients with noninfectious uveitis.

17 lammatory and autoimmune diseases, including uveitis.

18 evels to define sarcoidosis in patients with uveitis.

19 ertension (OHT) in adults with noninfectious uveitis.

20 ease has a weak to moderate association with uveitis.

21 -zoster virus-associated (5386 [1778] pg/mL) uveitis.

22 ith mild psoriasis have an increased risk of uveitis.

23 e signature in the vitreous of patients with uveitis.

24 al fluoroquinolones and an increased risk of uveitis.

25 an increased risk of noninfectious anterior uveitis.

26 lar pathways are altered in various forms of uveitis.

27 Caucasian man was diagnosed with unilateral uveitis.

28 ry parameters and anatomic classification of uveitis.

29 alateral eyes in individuals with unilateral uveitis.

30 virus and Toxoplasma gondii in patients with uveitis.

31 ter exclusion of eyes with herpetic anterior uveitis.

32 ing agent for the treatment of noninfectious uveitis.

33 fers protection from experimental autoimmune uveitis.

34 s the diagnosis of a patient with idiopathic uveitis.

35 4:1 ratio for comparison with patients with uveitis.

36 with noninfectious intermediate or posterior uveitis.

37 Measure: Presence of noninfectious anterior uveitis.

38 pen strategy, for the etiologic diagnosis of uveitis.

39 ectious causes and neoplastic masquerades of uveitis.

40 was blind (VA >20/400) in 38.5% of eyes with uveitis.

41 dalimumab in the treatment of JIA-associated uveitis.

42 an increased risk of noninfectious anterior uveitis.

43 m visual and other outcomes in patients with uveitis.

44 the association between thyroid disease and uveitis.

45 uring inflammation in a mouse model of human uveitis.

46 und in 6 of 131 eyes with glaucoma (4.6%) (3 uveitis, 1 prior hydrocephalus, 1 uveitis and pars plana

47 Of the 224 patients with uveitis (127 women and 97 men; mean [SD] age, 54.1 [17.8

48 ination of 341 patients revealed 46 cases of uveitis (13.5%), 6 cases of episcleritis (1.8%), and 3 c

49 (n = 12), central ECD was lower in eyes with uveitis (2324 cells/mm(2) [range, 1543-3289 cells/mm(2)]

50 yes (13.2%) (12 prior intraocular surgery, 5 uveitis, 3 primary retinopathy) and 6 of 76 nonglaucomat

51 igh proportion of seropositive OLM cases had uveitis (34.19%) followed by reduced vision (21.94%), vi

52 c anterior uveitis (48.3%), and intermediate uveitis (48.0%).

53 es with panuveitis (77.1%), chronic anterior uveitis (48.3%), and intermediate uveitis (48.0%).

54 rcentage hexagonality was lower in eyes with uveitis (54% [range, 33%-66%]) than in contralateral eye

55 of all uveitis patients) had an unclassified uveitis, 7 of whom underwent aqueous humor (n = 5) or vi

56 Two hundred thirty-seven eyes (70 active uveitis, 97 inactive uveitis, and 70 controls) were incl

57 Patients diagnosed with anterior uveitis (active or inactive) and controls.

58 ation coefficient [rho], 0.070, P = .27) nor uveitis activity and ACE (rho, -0.071; P = .27).

59 sided), but no association was found between uveitis activity and sIL-2R (Spearman rank correlation c

60 ritis also had an increased risk of incident uveitis (adjusted hazard ratio, 1.42; 95% CI, 1.23-1.64;

61 matory diseases, 224 cases were confirmed as uveitis after medical record review.

62 paired or blind in at least 1 eye because of uveitis, after a median of 9.7 years (range, 0-20.9 year

63 Bilateral uveitis (aHR, 0.69) and previous hypotony (aHR, 0.43) we

64 Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (

65 eitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (aHR, 5.2; 95% CI, 2.5-11), and panuveitis (aHR,

66 stic approach for the etiologic diagnosis of uveitis, although its noninferiority cannot be proved.

67 To evaluate the risk of incident uveitis among people with psoriasis.

68 hundred patients with noninfectious anterior uveitis and 100 patients without uveitis were recruited.

69 , at the Massachusetts Eye and Ear Infirmary Uveitis and Comprehensive Ophthalmology Clinics.

70 ntly higher ARI index compared with inactive uveitis and controls (both P < 0.0001).

71 count on OCT did not differ between inactive uveitis and controls, but was significantly higher in ac

72 es a common cytokine signature for posterior uveitis and guides the diagnosis of a patient with idiop

73 for diagnosing sarcoidosis in patients with uveitis and has slightly better diagnostic value than AC

74 cataract is common among pediatric eyes with uveitis and is most strongly related to the extent of in

75 11377 profoundly inhibited S-antigen-induced uveitis and laser-induced retinal neovascularization.

76 se of a man who developed bilateral anterior uveitis and macular serous retinal detachment during niv

77 To report a case of uveitis and neuroretinal detachment in a patient treated

78 tive therapy than COX inhibitors in treating uveitis and ocular diseases where neovascularization is

79 Frequency of ocular complications including uveitis and optic neuropathy in EVD survivors, level of

80 (4.6%) (3 uveitis, 1 prior hydrocephalus, 1 uveitis and pars plana vitrectomy, and 1 juvenile open-a

81 t to our knowledge, the relationship between uveitis and psoriasis is unsettled among researchers.

82 h uveitis and psoriatic arthritis and 1 with uveitis and psoriasis Observational Procedure: Retrospec

83 Five children with uveitis and psoriatic arthritis and 1 with uveitis and p

84 nosis of thyroid disease among patients with uveitis and respective controls.

85 y, is recommended to elucidate diagnoses for uveitis and scleritis/episcleritis.

86 To examine the clinical features of TB uveitis and the associations with response to antituberc

87 halmology referral centers diagnosed with TB uveitis and treated with ATT from January 1, 2004, throu

88 ion results that may warrant diagnosis of TB uveitis and treatment with ATT.

89 l of 21 patients developed an EVD-associated uveitis, and 3 patients developed an EVD-associated opti

90 y-seven eyes (70 active uveitis, 97 inactive uveitis, and 70 controls) were included.

91 in bilateral chronic noninfectious posterior uveitis, and is currently being treated using corticoste

92 sociated uveitis, many cases of intermediate uveitis, and most cases of posterior and panuveitides re

93 oninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted in the United Stat

94 oninfectious intermediate uveitis, posterior uveitis, and panuveitis.

95 oninfectious intermediate uveitis, posterior uveitis, and panuveitis.

96 oninfectious intermediate uveitis, posterior uveitis, and panuveitis.

97 oninfectious intermediate uveitis, posterior uveitis, and panuveitis.

98 systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with dif

99 level of VA impairment in EVD survivors with uveitis, and structural complications associated with VA

100 TSCM frequencies was found in AA, autoimmune uveitis, and systemic lupus erythematosus.

101 y with Trametinib and Dabrafenib was stopped uveitis anterior was seen 2 weeks later.

102 Patients with noninfectious uveitis are at risk for long-term complications of uncon

103 diagnostic tests for sarcoidosis-associated uveitis are needed because the currently available labor

104 a virus disease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessit

105 istic regression analysis was performed with uveitis as the main outcome variable and thyroid disease

106 peutic strategy for refractory and recurrent uveitis, as well as other inflammatory eye diseases.

107 hat occur in inflammatory diseases including uveitis, as well as prevention of trafficking of leukocy

108 second clinical report of bilateral anterior uveitis associated with macular serous retinal detachmen

109 pants were censored for a new diagnosis of a uveitis-associated systemic illness, the end of an obser

110 ed of any previous diagnosis of uveitis or a uveitis-associated systemic illness.

111 en oral fluoroquinolone use and the risk for uveitis-associated systemic illnesses, which is a possib

112 tivariate analysis, no hazard for developing uveitis at the 30-, 60-, or 90-day observation windows w

113 collected from 249 consecutive patients with uveitis at the Erasmus University Medical Center uveitis

114 and secondary glaucoma in herpetic anterior uveitis (AU), owing to either herpes simplex or varicell

115 comes in convalescence: new ocular symptoms, uveitis, auditory symptoms, and arthralgias.

116 data were extracted from medical records of uveitis cases.

117 tis seen between 1979 and 2007 at 5 tertiary uveitis clinics.

118 uveitis codes ranged from 0% to 100%, and 11 uveitis codes had a PPV exceeding 80%.

119 The PPVs for individual uveitis codes ranged from 0% to 100%, and 11 uveitis cod

120 rols, but was significantly higher in active uveitis compared to the other categories (both P < 0.000

121 I, 1.03-2.80; P = .04) higher odds of having uveitis compared with patients who did not have thyroid

122 arthritis had the greatest risk of incident uveitis compared with the nonpsoriatic controls (adjuste

123 minimal evaluation regardless of the type of uveitis (complete blood count, erythrocyte sedimentation

124 rior autoimmune noninfectious and nontumoral uveitis complicated by macular edema in at least 1 eye.

125 Uveitis control was correlated with an increase of IL-10

126 ng, participant category (active or inactive uveitis, control), age, gender, and central corneal thic

127 ab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids.

128 Furthermore, our uveitis data suggest that intrinsic immunoregulatory act

129 The hazard of a uveitis diagnosis after a fluoroquinolone prescription c

130 evaluate associated factors for a syphilitic uveitis diagnosis.

131 For patients with uveitis, disease activity (active vs. inactive) and grad

132 Longer total uveitis duration, bilateral uveitis, low visual acuity,

133 umber of inpatient admissions for syphilitic uveitis during the study period.

134 Experimental autoimmune uveitis (EAU), in which CD4(+) Th1 and/or Th17 cells are

135 n inducible model of experimental autoimmune uveitis (EAU).

136 fic T cells access the retina and autoimmune uveitis ensues.

137 as usually already present at the start of a uveitis episode.

138 One hundred five uveitis eyes (105 patients) with different vitreous haze

139 with cataract development were the number of uveitis flares per year (hazard ratio [HR] = 3.06 [95% c

140 the context of eyes with moderate to severe uveitis for years, this rate is not unexpected.

141 ARI index correlated with LFP in the active uveitis group (P < 0.0001), but not in the others.

142 Syphilitic uveitis had an annual incidence of 0.000045%, or 0.45 pe

143 Active uveitis had significantly higher ARI index compared with

144 lthough patients with sarcoidosis-associated uveitis had the highest mean (SD) serum sIL-2R (6047 [25

145 Intermediate uveitis has a long disease course with frequent complica

146 Uveitis has been associated with psoriatic arthritis, bu

147 use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity an

148 The frequency and severity of Blau uveitis highlight the need for close ophthalmologic surv

149 rd ratios (HRs) associated with intermediate uveitis (HR, 2.21; 95% CI, 1.07-4.55; P = .03), anterior

150 2.21; 95% CI, 1.07-4.55; P = .03), anterior uveitis (HR, 2.68; 95% CI, 1.32-2.35; P = .006), and pan

151 odds ratio [OR], 6.7; 95% CI, 1.5-31.2) and uveitis (HR, 5.7; 95% CI, 1.7-19.0; OR, 6.7; 95% CI, 1.5

152 as reported in 7.6% of the patients (n = 8), uveitis in 4.7% (n = 5), and hyphema in 3.7% (n = 4).

153 s various clinical features of noninfectious uveitis in humans.

154 xpressing B cells and ameliorates autoimmune uveitis in mice by antagonizing pathogenic Th17 response

155 be used therapeutically to limit autoimmune uveitis in mice.

156 We report the first incidence of syphilitic uveitis in the United States.

157 aminosis D was associated with noninfectious uveitis in the univariate analysis (odds ratio, 2.53; 95

158 evaluates the annual incidence of syphilitic uveitis in the US and trends in hospital admissions over

159 ence of cataract and distribution by type of uveitis, incidence of new onset cataract time to catarac

160 Anatomic subtypes of uveitis included anterior, posterior, and panuveitis in

161 to determine whether long-standing anterior uveitis increases risk of endothelial dysfunction, espec

162 Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6

163 STOP-Uveitis is a randomized, open-label safety, efficacy, an

164 Posterior uveitis is an ocular complication that can occur with re

165 Blau uveitis is characterized by progressive panuveitis with

166 Noninfectious uveitis is postulated to be caused by immune dysfunction

167 in juvenile idiopathic arthritis-associated uveitis (JIAU).

168 Longer total uveitis duration, bilateral uveitis, low visual acuity, high AC flare and LF grades,

169 of juvenile idiopathic arthritis-associated uveitis, many cases of intermediate uveitis, and most ca

170 Posterior uveitis may be an infrequent manifestation of tularemia

171 existing uncertainty in the diagnosis of TB uveitis may perpetuate missed opportunities to address s

172 All patients with JIA-associated uveitis (N = 108; affected eyes = 196) evaluated and fol

173 f eyes with surgery, variables for eyes with uveitis (n = 56) were compared with 2 historical populat

174 210, 76%), new ocular symptoms (n=167, 60%), uveitis (n=50, 18%), and auditory symptoms (n=67, 24%).

175 Importance: Noninfectious uveitis (NIU) is a collection of intraocular inflammator

176 e role of TCZ in patients with noninfectious uveitis (NIU).

177 oster virus, by using the Standardization of Uveitis Nomenclature (SUN) criteria, and to identify ris

178 ere recorded according to Standardization of Uveitis Nomenclature criteria.

179 ore that was based on the Standardization of Uveitis Nomenclature criteria.

180 analysis) included longer total duration of uveitis (odds ratio [OR] 1.13, P < .001), bilateral uvei

181 the development of cataract in children with uveitis of any etiology.

182 Aqueous PCR should be considered for uveitis of atypical clinical appearance, recurrent sever

183 ypical clinical appearance, recurrent severe uveitis of uncertain etiology, and therapy refractory ca

184 findings included anterior and intermediate uveitis, optic disc swelling, and white-yellowish choroi

185 , 9th Revision (ICD-9) code for syphilis and uveitis or (2) ICD-9 code for syphilitic uveitis.

186 teria consisted of any previous diagnosis of uveitis or a uveitis-associated systemic illness.

187 ADD, quadrant of ADD placement, diagnosis of uveitis or dry eye, and prior conjunctival surgery were

188 (odds ratio [OR] 1.13, P < .001), bilateral uveitis (OR 3.51, P = .009), low visual acuity (OR 5.1,

189 oninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU) and matched controls.

190 oninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having received prednison

191 ently active intermediate uveitis, posterior uveitis, or panuveitis enrolled in the Multicenter Stero

192 oninfectious intermediate uveitis, posterior uveitis, or panuveitis who do not respond to, or are int

193 oninfectious intermediate uveitis, posterior uveitis, or panuveitis.

194 ion between the presence of AAA+ and a worse uveitis outcome was observed only in patients with perma

195 tis at the Erasmus University Medical Center uveitis outpatient clinic, Rotterdam, the Netherlands, f

196 mber of IOP peaks during their follow-up for uveitis (P < .001).

197 neal thickness between eyes with and without uveitis (P = 0.27).

198 and A2Ar on T cells, and comparison between uveitis patients and healthy controls had no significant

199 We included uveitis patients attending a tertiary eye referral cente

200 We reviewed 1169 uveitis patients from Moorfields Eye Hospital, London, U

201 rmed B burgdorferi IgG seropositivity in our uveitis patients is only slightly lower as compared to t

202 Despite improved visual outcomes, uveitis patients receiving systemic immunosuppressive th

203 itis were identified from a database of 1254 uveitis patients seen in the clinic of a single consulta

204 changes in quality of life in noninfectious uveitis patients treated with 2 of the most commonly pre

205 The seroprevalence of B burgdorferi among uveitis patients was 3.7% (95% confidence interval 2.6%-

206 PBMC from uveitis patients were assayed for MC5r expression on mon

207 Uveitis patients were divided into active or inactive uv

208 Of these 42 patients, 14 (1.2% of all uveitis patients) had an unclassified uveitis, 7 of whom

209 ed practice guidelines for the evaluation of uveitis patients.

210 outine serologic examination for Borrelia in uveitis patients.

211 active (VISUAL-2) noninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted

212 steroid-dependent noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

213 CMT in eyes with noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

214 the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

215 for patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

216 een patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU) and m

217 ts who had active noninfectious intermediate uveitis, posterior uveitis, or panuveitis despite having

218 with active or recently active intermediate uveitis, posterior uveitis, or panuveitis enrolled in th

219 for patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis who do not res

220 tor, in eyes with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.

221 ECD was correlated to the duration of active uveitis (r = -0.41; P < 0.0001), maximum intraocular pre

222 novel spontaneous autoimmune mouse model of uveitis (R161H), we identified well-organized lymphoid a

223 All patients referred to our tertiary uveitis referral clinic in the period of from January 1,

224 Moreover, uveitis relapses were found up to 13 months after the ne

225 r eye-year, with an estimated 69% to develop uveitis-related cataract with time.

226 ctors potentially predictive of intermediate uveitis remission were evaluated using survival analysis

227 Noninfectious uveitis results in vision loss and ocular complications

228 inicians may use this finding as a guide for uveitis risk stratification among patients with differen

229 Patients aged >/=18 years with noninfectious uveitis seen between 1979 and 2007 at 5 tertiary uveitis

230 ased visual acuity, mild pain, and low-grade uveitis several weeks or months after intraocular surger

231 Oral SCFA administration attenuated uveitis severity in a mouse strain-dependent manner thro

232 hout prior history of intraocular surgery or uveitis should prompt further evaluation.

233 utive Committee and Trustees of the American Uveitis Society.

234 medical record review for confirmation by a uveitis specialist.

235 uveitis were diagnosed by fellowship-trained uveitis specialists after exclusion of infectious causes

236 Uveitis specialists have a high rate of laboratory testi

237 Using a set of uveitis-specific codes and eliminating patients with a h

238 atients were divided into active or inactive uveitis status according to clinical grading.

239 r observational follow-up of the Multicenter Uveitis Steroid Treatment (MUST) randomized clinical tri

240 The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Stu

241 redictors of treatment success in syphilitic uveitis (SU).

242 vide a novel diagnostic index of disease for uveitis subjects.

243 Follow-up was conducted in tertiary uveitis subspecialty practices in the United States (21)

244 type MCMV, lacking HEL, did not induce overt uveitis, suggesting that disease is mediated by antigen-

245 th acquired aplastic anemia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell d

246 g 10 mg/day, whereas a patient with inactive uveitis taking 35 mg/day of prednisone will experience,

247 s implies in turn that a patient with active uveitis taking 60 mg/day of prednisone will experience,

248 Central ECD was lower in eyes with uveitis than in control eyes for all age groups (P </= 0

249 The observations suggest that the uveitis that accompanies juvenile psoriatic arthritis mi

250 To describe the phenotype of the uveitis that accompanies juvenile psoriatic arthritis or

251 Two patients demonstrated asymptomatic uveitis that resolved without treatment.

252 n is sufficiently common in eyes treated for uveitis that surveillance for OHT is essential at all vi

253 SCFAs as a potential treatment strategy for uveitis through the stabilization of subclinical intesti

254 nt failure rate occurred in patients with TB uveitis treated with ATT.

255 ity improvement in the eyes of patients with uveitis treated with the fluocinolone acetonide implant

256 Although uveitis treatment was associated with increased vision a

257 ration of SFCAs, particularly propionate, on uveitis using an inducible model of experimental autoimm

258 fied patients with and without noninfectious uveitis using the Massachusetts Eye and Ear Infirmary Oc

259 was no change in the incidence of syphilitic uveitis, using either definition, over the study period

260 The mean annual incidence of syphilis and uveitis was 0.0004%, or 4 per million.

261 story of ocular surgery, the overall PPV for uveitis was 61% (95% CI, 56%-66%).

262 portance of this pathway in human autoimmune uveitis was assayed.

263 genicity was more common in patients in whom uveitis was associated with a systemic disease and was n

264 Recent diagnosis of uveitis was associated with an increased incidence of NV

265 valence of B burgdorferi among patients with uveitis was compared to the general population.

266 Remission of intermediate uveitis was defined as a lack of inflammatory activity a

267 The number of cases of syphilitic uveitis was defined by (1) International Classification

268 A clinical diagnosis of uveitis was determined through a query of the electronic

269 1861 patients (155 annually) and syphilitic uveitis was diagnosed in 204 subjects (average of 17 cas

270 Uveitis was most frequently unilateral (78.3%) and anter

271 The uveitis was posterior, with a 2+ vitritis and a large ye

272 Syphilis and uveitis was recorded for 1861 patients (155 annually) an

273 ions were diagnosed in 94 survivors (56.7%); uveitis was the most common (n = 57 [34%]).

274 Uveitis was unilateral in all cases and all patients dis

275 us adverse event, one of which (intermediate uveitis) was deemed related to the study regimen but res

276 1.60-5.50; P = .001) The odds of developing uveitis were 4% lower for every 1-ng/mL increase in vita

277 rated in the EAU model prior to the onset of uveitis were blunted by oral SCFA administration.

278 Patients with noninfectious uveitis were diagnosed by fellowship-trained uveitis spe

279 ions most commonly seen during follow-up for uveitis were elevated IOP (75%), keratitis (59%), dry ey

280 undred forty-seven eyes of 140 children with uveitis were evaluated for the development of vision-aff

281 Subjects with intermediate uveitis were identified from a database of 1254 uveitis

282 Nine hundred and three patients with uveitis were included from January 2010 to May 2013 and

283 The odds of syphilitic uveitis were lower among women (odds ratio [OR] 0.40, CI

284 us anterior uveitis and 100 patients without uveitis were recruited.

285 Cases of uveitis were reported several times.

286 Panuveitis and posterior uveitis were the most frequent findings.

287 wenty-two eyes of 16 pediatric patients with uveitis were treated with 35 dexamethasone implants at a

288 Five cases of glaucoma, including 1 with uveitis, were severe and associated with visual deterior

289 Survivors of EVD are at risk for uveitis, which may lead to secondary structural complica

290 Retinal NV is a rare complication of uveitis, which occurs more frequently in younger patient

291 At baseline 38 patients (78%) had uveitis, which was bilateral in 37 (97%).

292 Among patients with unilateral uveitis who had not undergone surgery in either eye (n =

293 Data were analyzed from 249 patients with uveitis who had their serum sIL-2R and ACE levels determ

294 ecutive patients with anterior and posterior uveitis who underwent AC paracentesis with PCR were revi

295 n and adolescents with active JIA-associated uveitis who were taking a stable dose of methotrexate.

296 Consecutive patients with uveitis, who visited 1 of the participating departments

297 However, an increased risk for incident uveitis with mild psoriasis without psoriatic arthritis

298 d association of structural complications of uveitis with visual impairment in a cohort of survivors

299 5% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years

300 Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the e